---
title: "Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286086400.md"
description: "Canaccord Genuity analyst Edward Nash has maintained a Buy rating for Apogee Therapeutics (APGE) with a price target of $130.00. The analyst has an average return of 25.7% and a 50.48% success rate on his stock recommendations. The overall analyst consensus for Apogee Therapeutics is a Strong Buy, with an average price target of $122.25."
datetime: "2026-05-12T11:06:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286086400.md)
  - [en](https://longbridge.com/en/news/286086400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286086400.md)
---

# Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Apogee Therapeutics today and set a price target of $130.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Kiniksa Pharmaceuticals. According to TipRanks, Nash has an average return of 25.7% and a 50.48% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apogee Therapeutics with a $122.25 average price target.

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [CORT.US](https://longbridge.com/en/quote/CORT.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [KNSA.US](https://longbridge.com/en/quote/KNSA.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)